699 related articles for article (PubMed ID: 17000960)
21. Relapses and progression of disability in multiple sclerosis.
Confavreux C; Vukusic S; Moreau T; Adeleine P
N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
[TBL] [Abstract][Full Text] [Related]
22. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors of multiple sclerosis in Lebanon.
Yamout B; Itani S; Arabi A; Hamzeh D; Yaghi S
Int J Neurosci; 2010 Mar; 120(3):206-10. PubMed ID: 20374088
[TBL] [Abstract][Full Text] [Related]
24. Cigarette smoking and progression in multiple sclerosis.
Koch M; van Harten A; Uyttenboogaart M; De Keyser J
Neurology; 2007 Oct; 69(15):1515-20. PubMed ID: 17923613
[TBL] [Abstract][Full Text] [Related]
25. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
26. Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later.
Scott TF; Schramke CJ
J Neurol Sci; 2010 May; 292(1-2):52-6. PubMed ID: 20202650
[TBL] [Abstract][Full Text] [Related]
27. A clinical longitudinal study of multiple sclerosis in Cantabria, Spain.
Morís G; Berciano J; Miró J
Neurologia; 2003 Dec; 18(10):723-30. PubMed ID: 14648348
[TBL] [Abstract][Full Text] [Related]
28. [Primary progressive forms of multiple sclerosis: application of the new diagnostic criteria in French].
De Seze J; Mackowiak A; Stojkovic T; Ferriby D; Hautecoeur P; Vermersch P
Rev Neurol (Paris); 2002 Mar; 158(3):341-5. PubMed ID: 11976594
[TBL] [Abstract][Full Text] [Related]
29. Multiple sclerosis in Australia: prognostic factors.
Hammond SR; McLeod JG; Macaskill P; English DR
J Clin Neurosci; 2000 Jan; 7(1):16-9. PubMed ID: 10847644
[TBL] [Abstract][Full Text] [Related]
30. Predictors of relapse rate in MS clinical trials.
Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
[TBL] [Abstract][Full Text] [Related]
31. Late onset multiple sclerosis.
Arias M; Dapena D; Arias-Rivas S; Costa E; López A; Prieto JM; Corredera E
Neurologia; 2011 Jun; 26(5):291-6. PubMed ID: 21163234
[TBL] [Abstract][Full Text] [Related]
32. Age at onset determines the occurrence of the progressive phase of multiple sclerosis.
Stankoff B; Mrejen S; Tourbah A; Fontaine B; Lyon-Caen O; Lubetzki C; Rosenheim M
Neurology; 2007 Mar; 68(10):779-81. PubMed ID: 17339588
[TBL] [Abstract][Full Text] [Related]
33. Age at disability milestones in multiple sclerosis.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):595-605. PubMed ID: 16415309
[TBL] [Abstract][Full Text] [Related]
34. Multiple sclerosis in Iraq: does it have the same features encountered in Western countries?
Al-Araji A; Mohammed AI
J Neurol Sci; 2005 Jul; 234(1-2):67-71. PubMed ID: 15946690
[TBL] [Abstract][Full Text] [Related]
35. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.
Glad SB; Nyland HI; Aarseth JH; Riise T; Myhr KM
Mult Scler; 2009 Aug; 15(8):942-50. PubMed ID: 19570821
[TBL] [Abstract][Full Text] [Related]
36. Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
[TBL] [Abstract][Full Text] [Related]
37. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P
Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422
[TBL] [Abstract][Full Text] [Related]
38. Timing of birth and disease progression in multiple sclerosis.
Koch M; De Keyser J; Tremlett H
Mult Scler; 2008 Jul; 14(6):793-8. PubMed ID: 18573829
[TBL] [Abstract][Full Text] [Related]
39. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
[TBL] [Abstract][Full Text] [Related]
40. Multiple sclerosis in Isfahan, Iran.
Saadatnia M; Etemadifar M; Maghzi AH
Int Rev Neurobiol; 2007; 79():357-75. PubMed ID: 17531850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
